Overexpression of MUC16 in lung cancer enhances tumor growth and migration, while also influencing development and metastasis through the JAK2/STAT3/GR axis, potentially contributing to chemotherapy resistance to agents like cisplatin and gemcitabine (56). Here, MUC16 is linked to lung carcinoma.